Short William R, Miller Emily S, Simone Joanne, Statton Anne, Finocchario-Kessler Sarah, Lampe Margaret
Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Open Forum Infect Dis. 2024 Jul 23;11(8):ofae423. doi: 10.1093/ofid/ofae423. eCollection 2024 Aug.
Pregnant persons with chronic health conditions often require pharmacotherapy to remain healthy. The Antiretroviral Pregnancy Registry is a prospective, international, voluntary, and exposure registry that collects information on antiretroviral (ARV) exposure; however, a minority of providers use the registry, leaving critical gaps to guide prescribing in this population. The Task Force for the Elimination of Perinatal HIV Transmission in the United States, funded by the Centers for Disease Control and Prevention, has identified the monitoring of ARV safety as a paramount concern in the ongoing mission to eliminate perinatal human immunodeficiency virus (HIV) transmission. As active members of this task force, we urge all healthcare providers who care for pregnant individuals to prioritize reporting all ARV exposures to the registry.
患有慢性健康状况的孕妇通常需要药物治疗来保持健康。抗逆转录病毒妊娠登记处是一个前瞻性、国际性、自愿性的暴露登记处,收集有关抗逆转录病毒(ARV)暴露的信息;然而,少数医疗服务提供者使用该登记处,导致在指导该人群用药方面存在关键空白。由疾病控制与预防中心资助的美国消除围产期HIV传播特别工作组已将监测抗逆转录病毒药物的安全性确定为正在进行的消除围产期人类免疫缺陷病毒(HIV)传播任务中的首要关注点。作为该特别工作组的积极成员,我们敦促所有为孕妇提供护理的医疗服务提供者将向登记处报告所有抗逆转录病毒药物暴露情况作为优先事项。